Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations

Key Points

• Patients with atypical EGFR mutations showed improved disease control with third-generation TKIs, enhancing progression-free survival.
• The study highlights that those with co-existing sensitizing mutations or CNS metastases experienced more notable benefits from TKIs.
• The analysis employed an integrated retrospective method, examining a subset of NSCLC patients with uncommon EGFR mutations.
• Overall, findings may inform treatment strategies, suggesting TKIs could play a vital role in managing these specific cases, but further validation is warranted.